Article Search

Granted, this is a small study of 12 patients, it is nice to see an official report indicating safety regarding the use of CPI in the setting of advanced cutaneous SCC’s secondary to chronic immunosuppressive therapy after renal transplant. Patients were treated with steroids and rapamycin before/after the cemiplimab infusions, and no patients had rejection events.

Impressive phase II results from MDA, confirming many of our prior anecdotal experiences with this drug. Not a randomized study but it is now approved in the locally advanced and metastatic setting. Responses were seen across all subgroups including PD1-neg patients.